Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.47 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.40 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.38 |
| ▸ | MAP3K6 | O95382 | 2/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GPR3 | P46089 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | CCNK | O75909 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CDK7 | P50613 | 1/20 | 0.36 |
| ▸ | CCNH | P51946 | 1/20 | 0.36 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.36 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31548018 | 1.00 | MAP3K5 (0.47) | MAP3K5FDPSNPSR1PCSK9MAP3K7 | |
| SCHEMBL31143762 | 0.82 | MAP3K5 (0.54) | MAP3K5FDPSNPSR1PCSK9MAP3K7 | |
| SCHEMBL8986816 | 0.82 | MAP3K5 (0.54) | MAP3K5FDPSNPSR1PCSK9MAP3K7 | |
| SCHEMBL1483456 | 0.77 | MAP3K5 (0.68) | MAP3K5FDPSPCSK9MAP3K7MAP3K6 | |
| SCHEMBL2338189 | 0.77 | MAPT (0.46) | MAP3K5FDPSPCSK9ROCK1KDM4E | |
| SCHEMBL30961064 | 0.77 | MAPT (0.46) | MAP3K5FDPSPCSK9ROCK1KDM4E | |
| SCHEMBL28184943 | 0.77 | FDPS (0.48) | MAP3K5FDPSPCSK9ROCK1KDM4E | |
| SCHEMBL6467426 | 0.77 | MAP3K5 (0.54) | MAP3K5FDPSPCSK9ROCK1KDM4E | |
| SCHEMBL6307534 | 0.75 | NPC1 (0.58) | MAP3K5FDPSKDM4ECYP1A2PLAU | |
| SCHEMBL28347289 | 0.75 | MAP3K5 (0.50) | MAP3K5FDPSPCSK9MAP3K7MAP3K6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124562-A1 | Bis-quinazoline compounds for the treatment of bacterial infections | REPLIDYNE, INC. | 2005-06-09 | — | — | US | claimed |
| WO-2005030131-A2 | BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | REPLIDYNE, INC (US) | 2005-04-07 | — | — | WO | claimed |
| US-20230183187-A1 | QUINAZOLINE COMPOUNDS AS INHIBITORS OF PREMATURE TERMINATION CODONS | CENTRE NAT RECH SCIENT (FR) | 2023-06-15 | — | — | US | disclosed |
| EP-4149930-A1 | QUINAZOLINE COMPOUNDS AS INHIBITORS OF PREMATURE TERMINATION CODONS | Centre national de la recherche scientifique (FR) | 2023-03-22 | — | — | EP | disclosed |
| WO-2021228945-A1 | QUINAZOLINE COMPOUNDS AS INHIBITORS OF PREMATURE TERMINATION CODONS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-11-18 | — | — | WO | disclosed |
| WO-2020263164-A1 | COMPOUNDS TARGETING DUAL G-QUADRUPLEX DNA AND STAT3 | SABOURI NASIM (SE) | 2020-12-30 | — | — | WO | disclosed |
| US-20180002295-A1 | Compositions and Methods for Treating Anxiety and Compulsive Behavior | UNIV IOWA RES FOUND (US) | 2018-01-04 | — | — | US | disclosed |
| US-9550788-B2 | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof | SANOFI (FR) | 2017-01-24 | — | — | US | disclosed |
| EP-2342178-B1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | SANOFI SA (FR) | 2016-09-28 | — | — | EP | disclosed |
| WO-2016118952-A1 | COMPOSITIONS AND METHODS FOR TREATING ANXIETY AND COMPULSIVE BEHAVIOR | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2016-07-28 | — | — | WO | disclosed |
| US-20140349986-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2014-11-27 | — | — | US | disclosed |
| US-20040006119-A1 | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-01-08 | — | — | US | disclosed |
| CN-1450996-A | 2-guanidino-4-aryl-quinazoline | MERCK PATENT GMBH (DE) | 2003-10-22 | — | — | CN | disclosed |
| US-20030187045-A1 | Substituted imidazolidines, process for their preparation, and their use as a medicament or diagnostic | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-10-02 | — | — | US | disclosed |
| US-20030176314-A1 | Compounds for the treatment of pain | H. LUNDBECK A/S (DK) | 2003-09-18 | — | — | US | disclosed |
| US-20030139431-A1 | Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors | H. LUNDBECK A/S (DK) | 2003-07-24 | — | — | US | disclosed |
| CN-1422260-A | 2-guanidino-4-arylchinazolines as NHE-3 inhibitors | MERCK PATENT GMBH (DE) | 2003-06-04 | — | — | CN | disclosed |
| WO-2003026657-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003026667-A1 | QUINAZOLINO- AND QUINOLINO- GUANIDINES AS LIGANDS FOR THE NEUROP EPTIDE FF (NPFF) RECEPTORS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| US-4128643-A | 4-Quinazolinyl-guanidines | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006119-A1 | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis | TST, GOT2, ALPP | MAP3K5 3720/4885FDPS 110/4885NPSR1 1123/4885 |
| US-20030187045-A1 | Substituted imidazolidines, process for their preparation, and their use as a medicament or diagnostic | CHRM1, ARG2, ACHE | MAP3K5 2932/4885FDPS 1533/4885NPSR1 1424/4885 |
| US-20030176314-A1 | Compounds for the treatment of pain | NPFFR2, NPFFR1, OPRL1 | MAP3K5 3329/4885FDPS 3163/4885NPSR1 4/4885 |
| US-20180002295-A1 | Compositions and Methods for Treating Anxiety and Compulsive Behavior | HCRTR1, CHAT, CRH | MAP3K5 4512/4885FDPS 4510/4885NPSR1 33/4885 |
| US-20050124562-A1 | Bis-quinazoline compounds for the treatment of bacterial infections | POLI, POLK, POLB | MAP3K5 2241/4885FDPS 881/4885NPSR1 4093/4885 |
| US-20230183187-A1 | QUINAZOLINE COMPOUNDS AS INHIBITORS OF PREMATURE TERMINATION CODONS | UPF1, NUDT21, REV1 | MAP3K5 1094/4885FDPS 1178/4885NPSR1 3334/4885 |
| US-20030139431-A1 | Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors | NPFFR1, NPFFR2, SSTR3 | MAP3K5 4647/4885FDPS 4296/4885NPSR1 39/4885 |
| US-20140349986-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | CFTR, AADAT, FANCI | MAP3K5 3617/4885FDPS 192/4885NPSR1 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.